Given the autosomal dominant nature of BVMD, gene supplementation therapy, effectively demonstrated for RPE65-Leber congenital amaurosis, will likely not be successful as gene replacement will not counteract the effect of gain-of-function mutants in BVMD29–32. This evidence concerns the gene RPE65 and Best vitelliform macular dystrophy.